Almost 30 million prescriptions for Ritalin and similar drugs to
treat attention deficit hyperactivity disorder (ADHD) were written
last year in the United States; 23 million were for children. While
these drugs are among the most widely prescribed medicines in the
world, they also remain one of the most controversial.
The latest chapter in the debate over the safety of ADHD drugs:
The Food and Drug Administration's (FDA) investigation regarding
a link between Ritalin and cancer -- based on a small University
of Texas study.
The findings showed damage to the chromosomes of 12 children who
had taken Ritalin for three months.
And while the Texas researchers claimed their study was far too
small to prompt the parents of attention deficit patients to abandon
Ritalin and may contain some methodology flaws, the FDA, National
Institutes of Health (NIH) and the Environmental Protection Agency
found the results merited public concern and further study.
A grant proposal is in the works at the NIH to fund a much larger
probe in 2006, involving many more patients and a variety of drugs.
Labeling Changes?
The news about Ritalin's possible link to cancer comes in juxtaposition
with another health issue surrounding the class of ADHD medications
known as methylphenidates, to which Ritalin belongs.
In fact, the FDA has been considering labeling changes to all methylphenidates
due to potential psychiatric events and cardiovascular side effects.
A previous review uncovered:
-
Thirty-six psychiatric events (such as hallucinations and suicide
ideation) for Concerta, compared to 16 for Ritalin and other
methylphenidates.
-
Concerta had 20 cardiovascular event reports; other methylphenidates
had four.
Some critics, however, believe labeling changes may not be the
answer.
According to the director of the child and adolescent psychiatry
clinic at Jackson Memorial Hospital and an associate professor of
psychiatry at the University of Miami School of Medicine, labeling
is an oversimplification of the problem and doesn't address the
many other problems that are affecting the outcome.
Cancer
Letters February 16, 2005
New
York Times July 1, 2005
Forbes
July 1, 2005
|